Table 2.

Summary of the applied therapies as reported in each eligible article.

Study	Intervention group	Dose	Regime	Duration (days)	Control group	Dose	Regime	Duration (days)
Wang et al. (2013)27	Ulinastatin + somatostatin	100000 U	q12h	10	Somatostatin	250 mcg/h	Continuous	10
Tu et al. (2014)28	Ulinastatin + octreotide	200000 U	qd	14	Octreotide	0.5 g/(kg x h)	N/A	14
Guo et al. (2015)13	Ulinastatin + octreotide	(1) 100000 U (2) 50000 U	(1) q12h (2) q12h	(1) for 3 (2) then 7–14	Octreotide	0.1 mg	q8h	7–14
Wang et al. (2016)14	Ulinastatin + somatostatin	100000 U	q12h	10	Somatostatin	3 mg	Continuous	10
Wang et al. (2017)30	Ulinastatin + somatostatin	100000U	(1) q12h (2) q24h	(1) for 3 (2) then 7	Somatostatin	6 mg	Continuous	10
Yang et al. (2017)32	Ulinastatin + octreotide	100000 U	q12h	10	Octreotide	0.1 mg	q6h	7
Yang et al. (2018)15	Ulinastatin + octreotide	200000 U	qd	14	Octreotide	0.1 mg bolus + 25 mcg/h	Continuous	14
Meng et al. (2019)31	Ulinastatin + octreotide	100000U	q12h	7	Octreotide	0.6 mg	Continuous	7
Xu et al. (2019)29	Ulinastatin + somatostatin	100000 U	q24h	7	Somatostatin	6 mg	Continuous	7

U, unit; q, every; h, hour; d, day; mcg, microgram; mg, milligram, N/A, not reported.